FindTrial
Sign In

A randomised, double-blind, placebo-controlled Phase IIIb Study investigating changes in immunological parameters and cutaneous reactivity induced by a short course immunotherapy with ALK grass tablets.

A randomised, double-blind, placebo-controlled Phase IIIb Study investigating changes in immunological parameters and cutaneous reactivity induced by a short course immunotherapy with ALK grass tablets.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-005263-26-ES
Enrollment
75
Registered
2012-03-30
Start date
2006-12-19
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.1 Level: PT Classification code 10039085 Term: Rhinitis allergic System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders

Interventions

Trade Name: GRAZAX 75000 SQ-T liofilizado oral Product Name: GRAZAX 75000 SQ-T liofilizado oral Pharmaceutical Form: Oral lyophilisate INN or Proposed INN: Extracto alergénico estandarizado de polen d

Sponsors

ALK-Abelló, S.A.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 75 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Spain

Contacts

Public ContactPilar Rico

ALK-Abelló, S.A.

pilar.rico@alk-abello.comNANA+34 91 327 61 27NA

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026